Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: A pilot study

Aging Male

Volumn 11, Issue 2, 2008, Pages 57-61

  Kalinchenko, S ^a,b   Vishnevskiy, E L ^a   Koval, A N ^a   Mskhalaya, G J ^a   Saad, F ^a  

^a ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Aging Male Symptoms scale; Erectile function; Late onset hypogonadism; LUTS; Testosterone

Indexed keywords

SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HUMAN; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; MALE; PILOT STUDY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; AGE OF ONSET; AGED; AGING; HUMANS; HYPOGONADISM; MALE; MEN; MIDDLE AGED; PILOT PROJECTS; TESTOSTERONE; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 45849143339     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530801953994     Document Type: Article

References (31)

1. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS - implications for clinical practice. Andrologia 2006;38(1):1-12.
2. Abrams P. Benign prostatic hyperplasia. Poorly correlated with symptoms. BMJ 1993;307(6897):201.
3. Griffiths CJ, Harding C, Blake C, McIntosh S, Drinnan MJ, Robson WA, Abrams P, Ramsden PD, Pickard RS. A nomogram to classify men with lower urinary tract symptoms using urine flow and noninvasive measurement of bladder pressure. J Urol 2005;174(4Pt1):1323-1326; discussion:1326; author reply: 1326.
4. Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000;85(Suppl.3):57-68; discussion:70-51.
5. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up study. Urology 2002;59(2): 245-250.
6. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51(1):207-215; discussion:215-206.
7. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26(6):833-876.
8. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63(3):239-250.
9. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004;25(3):389-425.
10. Yassin AA, Saad F. Erectile dysfunction, metabolic syndrome, hypogonadism are intertwined. J Urol 2007;177:288.
11. Rosen RC. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 2006;16(1):11-19.
12. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97(Suppl.2):23-28; discussion:44-25.
13. Glina S, Santana AW, Azank F, Mello LF, Moreira ED Jr. Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. BJU Int 2006;97(4): 763-765.
14. Paick JS, Yang JH, Kim SW, Ku JH. Are age, anthropometry and components of metabolic syndrome-risk factors interrelated with lower urinary tract symptoms in patients with erectile dysfunction? A prospective study. Asian J Androl 2007;9(2):213-220.
15. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006;7(4):288-292.
16. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005; 29(3):310-316.
17. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006; 65(3):275-281.
18. Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, Moore C, Saad F, Potthoff P, Thai do M. The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003;1(1):77.
19. Mskhalaya G, Rozhivanov RV, Nesterov MN, Kalinchenko SY. The efficiency and safety of human chorionic gonadotropin (HCG) therapy on low urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Paper presented at the Fifth Congress of The International Society for the Study of The Aging Male. Salzburg, Austria, February 2006.
20. Karazindiyanoǧlu S, Çayan S. Beneficial effects of testosterone administration of bladder function. Sixth Annual Meeting of the European Association of Urology. Berlin, Germany, March 2007.
21. Mskhalaya G, Tishova JA, Koval AN, Vishnevskiy EL, Kalinchenko SY. The efficiency of testosterone undecanoate (Nebido) therapy on lower urinary tract symptoms (LUTS) in men with late-onset hypogonadism (LOH). First European Congress of the Society for the Study of the Aging Male. Warsaw, Poland; June 2007. Abstract Book: 36.
22. Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29(1): 102-105.
23. Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007;19(4):386-392.
24. Rosenzweig BA, Bolina PS, Birch L, Moran C, Marcovici I, Prins GS. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 1995;14(1):87-96.
25. Keast JR. The autonomic nerve supply of male sex organs - an important target of circulating androgens. Behav Brain Res 1999;105(1):81-92.
26. Watkins TW, Keast JR. Androgen-sensitive preganglionic neurons innervate the male rat pelvic ganglion. Neuroscience 1999;93(3):1147-1157.
27. Hall R, Andrews PL, Hoyle CH. Effects of testosterone on neuromuscular transmission in rat isolated urinary bladder. Eur J Pharmacol 2002;449(3):301-309.
28. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Barbara Vannelli G, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148(3):1019-1029.
29. Muto S, Yasuda M, Kamiyama Y, Ide H, Horie S. Testosterone decreased urinary frequency in nNOS-deficient mice. Int J Androl 2007;31:67-70.
30. McVary KT. Unexpected insights into pelvic function following phosphodiesterase manipulation - what's next for urology? Eur Urol 2006;50(6):1153-1156.
31. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91(6):1995-2010.